Robert S. Kerbel

Sunnybrook Health Science Centre — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

111h-index54.0kcitations676works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(234), Cancer, Hypoxia, and Metabolism(122), Cancer Cells and Metastasis(91), Cancer Treatment and Pharmacology(80), Cancer Genomics and Diagnostics(68)

Publications675 total

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade
Cell Reports Medicine·2025Open Access
Supplementary Figure S6 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S2 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Data from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S9 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S8 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S4 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S3 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S7 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S1 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Supplementary Figure S5 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
2025Open Access
Novel allelic variants in Sanjad-Sakati and Kenny-Caffey syndromes identified by whole exome sequencing
Endocrine Abstracts·2025
Abstract 1277: <i>Ex ovo</i> system for rapid and quantitative modelling of immunotherapy responses in pre-clinical and patient-derived xenografts: PDX<i>ovo</i>
Cancer Research·2025
Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Cancer Research·2025Open Access
Metronomic chemotherapy and drug repurposing: Two sides of an oncology coin to reduce host and financial toxicity
Cancer Letters·2025· 3 cited
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model
Cancers·2024· 1 citedOpen Access
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Nature Reviews Clinical Oncology·2024· 78 cited
Abstract 1353: Potentiating salvage radiotherapy in radiorecurrent prostate cancer through anti-CTLA4 therapy: Implications from a syngeneic model
Cancer Research·2024
Abstract A025: Combination of anti-CTLA4 and radiation induce synergistic tumor control in radiorecurrent prostate cancer
Cancer Immunology Research·2023· 1 cited
Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice
Cancer Research·2023
page 1 of 34Next →

Frequent Co-authors

Yuval Shaked(12), Janusz Rak(11), Shan Man(11), Daniel J. Hicklin(8), Francesco Bertolini(7), Christina R. Lee(5), John M.L. Ebos(4), Peter Böhlen(4), Guido Bocci(4), Patrizia Mancuso(4), Marco Colleoni(3), Brad St. Croix(3), Giulio Francia(3), Napoleone Ferrara(2), William Cruz‐Muñoz(2), James G. Christensen(2), Giannoula Klement(2), Sylvain Baruchel(2), Charles H. Graham(2), Adrian L. Harris(2)